Atlas.
Sign inStart free trial
HALONASDAQ · US

HALOZYME THERAPEUTICS, INC.

Technology · Biological Products, (No Diagnostic Substances)

TechnologyBiological Products, (No Diagnostic Substances)
CEO
Helen Torley, M.B. Ch.B., M.R.C.P.
Founded
—
IPO Date
—
HQ
San Diego, CA, United States
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$77.01 ▲ 9.5%
Last (1 Jul 2026) · $77
Period High · $81.23
Period Low · $61.63
52W: $54.00 – $81.23

Key Metrics

Share Price
$77.01
-1.6% today
Market Cap
$9.1B
P / E
28.6x
EV / Revenue
7.9x
Revenue Growth
+37.5%
year-on-year
Gross Margin
—
Enterprise Value
$11.1B
52W High
$81.23
52W Low
$54.00
Avg Volume
1.6M
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
3 known institutional holders·$29M total on record·2026-Q1
Jpmorgan Chase & Co
15.4%·$19M
Point72 Asset Management, L.P.
6.4%·$8M
Fmr LLC
2.0%·$2M
Free Float
76.2%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for HALOZYME THERAPEUTICS, INC.
OverviewHALOZYME THERAPEUTICS, INC. share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow HALOZYME THERAPEUTICS, INC. generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsHALOZYME THERAPEUTICS, INC.'s complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityHALOZYME THERAPEUTICS, INC. executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsHALOZYME THERAPEUTICS, INC.'s annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for HALOZYME THERAPEUTICS, INC., updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for HALOZYME THERAPEUTICS, INC. aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersHALOZYME THERAPEUTICS, INC. valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for HALOZYME THERAPEUTICS, INC. with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for HALOZYME THERAPEUTICS, INC. — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial